Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis CRoberta D’Ambrosio, S. Fagiuoli, Francesca Capelli et al.|Journal of Hepatology|2018Cited by 132
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV InfectionElisabetta Degasperi, Pietro Lampertico, Roberta D’Ambrosio et al.|Clinical Gastroenterology and Hepatology|2018Cited by 114
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVRRoberta D’Ambrosio, Pietro Lampertico, Elisabetta Degasperi et al.|Journal of Hepatology|2021Cited by 75
Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAsElisabetta Degasperi, Pietro Lampertico, E. Galmozzi et al.|Hepatology|2020Cited by 67
A new clinical and prognostic characterization of the patterns of decompensation of cirrhosisMarta Tonon, Paolo Angeli, Valeria Calvino et al.|Journal of Hepatology|2023Cited by 61